They also provide support for the benefit of IV idursulfase on somatic manifestations of MPS II even when initiated later in the disease course, although the most favorable overall outcomes are likely to be observed in patients starting ERT before the age of 18 months. The gene discussed is IDS; the disease is mucopolysaccharidosis type 2.